Claims for Patent: 5,747,510

Summary for Patent: 5,747,510

Title:	Pharmaceutical unit dosage formulations
Abstract:	A method of inhibiting bone loss or resorption, or lowering serum cholesterol, comprising administering to a human in need thereof a compound having the formula ##STR1## or a pharmaceutically acceptable salt or solvate thereof, in a low dosage amount. Also encompased by the invention is a a pharmaceutical formulation in unit dosage form comprising, per unit dosage, a low dosage amount.
Inventor(s):	Draper; Michael W. (Carmel, IN)
Assignee:	Eli Lilly and Company (Indianapolis, IN)
Application Number:	08/788,984
Patent Claims:	1. A pharmaceutical formulation in daily dosage unit form comprising, per daily dosage unit, an amount within the range of about 55 to about 150 mg of a compound of formula I ##STR3## or a pharmaceutically acceptable salt or solvate thereof, said formulation in dosage unit form being adapted for oral administration in the form of a capsule or tablet. 2. A pharmaceutical formulation of claim 1 in a form adapted for administration to inhibit bone loss. 3. A pharmaceutical formulation of claim 1 in a form adapted for administration to lower serum cholesterol or. 4. A pharmaceutical formulation of claim 1 in the form of a capsule. 5. A pharmaceutical formulation of claim 1 in the form of a tablet. 6. A pharmaceutical formulation of claim 1 in the form of a suspension. 7. A pharmaceutical formulation of claim 1 wherein the dosage unit comprises 60 mg of a compound of formula I. 8. A pharmaceutical formulation of claim 1 wherein the dosage unit comprises 75 mg of a compound of formula I. 9. A pharmaceutical formulation of claim 1 wherein the dosage unit comprises 100 mg of a compound of formula I. 10. A pharmaceutical formulation of claim 1 wherein the dosage unit comprises 125 mg of a compound of formula I. 11. A pharmaceutical formulation of claim 1 wherein the dosage unit comprises 150 mg of a compound of formula I. 12. A pharmaceutical formulation of claim 1 wherein said formulation is in the form of a capsule. 13. A pharmaceutical formulation of claim 12 wherein the dosage unit comprises 60 mg of a compound of formula I. 14. A pharmaceutical formulation of claim 12 wherein said formulation is adapted for inhibiting bone loss or bone resorption, or lowering serum lipid levels.